ABSTRACT N-Methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity is thought to underlie a variety of neurological disorders, and inhibition of either the NMDA receptor itself, or molecules of the intracellular cascade, may attenuate neurodegeneration in these diseases. Calpain, a calcium-dependent cysteine protease, has been identified as part of such an NMDA receptorinduced excitotoxic signaling pathway. The present study addressed the question of whether inhibition of calpain can prevent neuronal cell death and associated behavioral deficits in a disease-relevant animal model, which is based on excitotoxic lesions of the cholinergic nucleus basalis magnocellularis of Meynert. Excitotoxic lesions of the nucleus basalis with NMDA induced a markedly impaired performance in the novel object recognition test. Treatment with the calpain inhibitor,
choline acetyltransferase in the cortical mantle of the lesioned animals revealed that application of A-705253 dose-dependently and significantly attenuated cholinergic neurodegeneration. Calpain inhibition also significantly diminished the accompanying gliosis, as determined by immunohistochemical analysis of microglia activation. Finally, inhibition of calpain by A-705253 and the peptidic calpain inhibitor N-acetyl-Leu-LeuNle-CHO did not impair long-term potentiation in hippocampal slices, indicating that calpain inhibition interrupts NMDA excitotoxicity pathways without interfering with NMDA receptormediated signaling involved in cognition. We conclude that inhibition of calpains may represent a valuable strategy for the prevention of excitotoxicity-induced neuronal decline without interfering with the physiological neuronal functions associated with learning and memory processes. Thus, calpain inhibition may be a promising and novel approach for the treatment of various neurodegenerative disorders.
Calpains in the central nervous system are Ca 2ϩ -dependent cysteine proteases, which can modulate the conformation, localization, and activity of various proteins. Calpaininduced modifications have a profound affect on biological processes as different as cell cycle progression and vesicular trafficking. They are an integrative part of several signaling cascades, but they can also contribute to apoptotic and necrotic cell death in pathological conditions. For this reason, calpains have been discussed extensively as target for therapeutic interventions in a number of neurodegenerative disease that are associated with neuronal loss (for review, see Huang and Wang, 2001; Goll et al., 2003; Zatz and Starling, 2005) .
In that respect, it has recently been shown that inhibition of calpains prevents excitotoxic neuronal cell death in vitro (Caba et al., 2002; Ray et al., 2006) and in vivo (Chiu et al., 2005; Takano et al., 2005) . Excitotoxicity is caused by an overstimulation of N-methyl-D-aspartate (NMDA) receptors, and there is now growing evidence that calpain cleaves sev-eral downstream targets that are critical for the progression of excitotoxic neuronal degenerative processes (Wu et al., 2004; Hou et al., 2006) .
We have recently introduced a highly specific low-molecular-weight inhibitor of calpain, A-705253, which does not affect the multifunctional proteasome complex . Selectivity against the proteasome is necessary to evaluate the role of calpain, because the ubiquitin-proteasome system also contributes to some neurodegenerative diseases (Rubinsztein, 2006; Pan et al., 2008) . By using such a specific calpain inhibitor, we addressed the questions of whether inhibition of calpain-mediated cascades would 1) prevent neurodegeneration in a model relevant for neurodegenerative diseases, 2) maintain the behavioral function of the affected brain area, and 3) affect normal NMDA receptordependent physiology. To analyze the neuroprotective effect of calpain inhibition, we used an established model of excitotoxicity-induced nucleus basalis magnocellularis (NBM) degeneration in rats (Horvá th et al., 2000; Harkany et al., 2001 Harkany et al., , 2002 . The NBM in rats is analogous to the nucleus basalis of Meynert in humans. Cholinergic fibers originating from the NBM extensively project to the neocortical mantle and play an essential role in the attention phase of information storage processing (Blokland 1995; Van der Zee and Luiten 1999) . Lesioning of the NBM in rodents causes a degeneration of cholinergic cortical projections, which inevitably leads to severe cognitive deficits in affected rats and mimics the characteristic loss of forebrain cholinergic innervation in Alzheimer's disease (Bartus et al., 1982; Gaykema et al., 1992) . Compounds that interfere with downstream calcium-associated intracellular pathways initiated by glutamate-induced calcium influx may well affect signaling cascades that are crucial for memory processes. To assess whether calpain inhibition would affect normal NMDA-dependent physiology, we also examined long-term potentiation (LTP) in hippocampal slices.
In this study, we present data showing that calpain inhibition prevents NMDA-induced neurodegeneration of NBM and associated decrease of cortical cholinergic innervation. Furthermore, calpain inhibition attenuates cognitive deficits that occur as a result of such neurodegeneration. Normal NMDA receptor-dependent physiology is not affected, indicating that only those downstream cascades are interrupted, which contribute to cellular pathology.
Materials and Methods

Materials
A-705253 was solubilized in 0.9% sodium chloride with a pH between 5 and 5.5, and injected intraperitoneally in doses of 1, 3, and 10 mg/kg b.wt. NMDA (Sigma-Aldrich, St. Louis, MO) solution was prepared in phosphate-buffered saline (PBS) solution (pH7.4) in a concentration of 60 nmol per 1 l. The selective noncompetitive NMDA receptor antagonist (ϩ)-MK-801 hydrogen maleate (Sigma-Aldrich) was dissolved in 0.9% sodium chloride for intraperitoneal injection in a dose of 2.5 mg/kg. N-Acetyl-Leu-LeuNle-CHO (ALLN; Calbiochem, San Diego, CA) stock solutions were prepared in dimethyl sulfoxide.
Animals and Surgical Procedure
Eight-month-old male Wistar rats (8 -11 per group; Harlan, Borchen, Germany) were anesthetized with an intraperitoneal injection of sodium pentobarbital (60 mg/kg b.wt.). All care and treatments were carried out in accordance with the European Communities Council Directive on the use of experimental animals. One microliter of the freshly prepared solution of NMDA (60 nmol) in PBS was applied by a Hamilton microsyringe into the right nucleus basalis (anterior-posterior coordinate, Ϫ1.5 mm; lateral, 3.2 mm) at two dorsoventral positions, 6.2 and 7.0 mm ventral to the dura. Sham controls followed the same surgical procedures, but they were injected with the same quantity of the PBS alone. For more methodological details, we can refer to our earlier report (Luiten et al., 1995) .
Drug Administration
A-705253, MK-801, or vehicle were applied 1 h before NMDA injection, which was followed by a second application 12 h after surgery and 2 daily injections for the next 2 days. MK-801 was also injected 1 h before and 12 h after surgery, but it was given only once per day for the two postsurgery days (at 2.5 mg/kg).
At postoperative day 12, the animals were transcardially perfused under deep pentobarbital anesthesia with a fixative solution of 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, after a short prerinse with heparinized saline. The brains were removed, postfixed for 2 days in the same fixative, and stored in phosphate buffer at 0°C, then cryoprotected by 30% sucrose for 4 days, and sectioned on a cryostat microtome at a thickness of 20 m. Free-floating brain sections were processed for immunocytochemical staining.
ChAT Staining of Cholinergic Fibers
An immunostaining procedure was applied to visualize choline acetyltransferase (ChAT)-positive cholinergic neurons in NBM and their projection axon ramifications in the target brain areas, i.e., in the parietal neocortex. Every eighth section was stained for ChAT and CD11b as a microglia marker. Goat anti-ChAT primary antibody (Chemicon, Temecula, CA) was used in a 1:500 dilution. Biotinylated rabbit anti-goat antibody and Vectastain ACB kit was obtained from Vector Laboratories (Burlingame, CA). The staining was completed with nickel-enhanced diaminobenzidine reaction in the presence of H 2 O 2 .
Visualization of Microglial Activation by CD11b Antibody
Mouse anti-rat integrin ␣M [CD11b] monoclonal antibody (Chemicon) was used in a dilution rate of 1:1500 to recognize activated microglia. The biotinylated secondary antibody and the ABC kit were obtained from Vector Laboratories (see above). Diaminobenzidine reaction was enhanced by nickel ammonium sulfate, as described above.
Quantification of Cholinergic Fiber Density
The quantification procedure for cholinergic fiber density is established in our laboratory and was published several times in the past (Horvá th et al., 2000; Harkany et al., 2001) . In brief, the parietal neocortex, topographically corresponding to the anterior-posterior site of the NMDA lesion in the NBM and with the highest level of cholinergic fiber loss, was analyzed for fiber density with the Quantimet 600HR (Leica, Wetzlar, Germany) computer program. The exact measurement took place in the superficial sublayer of the layer V cortical area, which receives the highest density of cholinergic innervation. Three brain sections were analyzed per animal, and the results were averaged. Fiber density in percentage surface area of positively stained fibers was computed in both sides of the brain section. The ChAT-positive fiber density ipsilateral to the lesion was compared with the intact contralateral side, and the percentage loss was calculated as an indicator of cholinergic neuron and fiber degeneration.
Magnitude of Microglial Reaction
Microglial activation around the lesion was remarkably localized and could be quantified with a computerized technique that mea-sured the size of the brain region infiltrated by the activated microglia (Quantimet; Leica). Area of microglial activation was manually delineated and measured at the level of NBM injection indicated by the overstained injection channel. Here again, three sections were selected from a total of 10 to 12 for measurements. The selection of sections and measurements were unbiased and carried out blindly.
Behavioral Testing
Small Open-Field Behavior. Seventy-two hours postsurgery, the behavior of the animals was assessed in a light-independent small open-field paradigm (Nyakas et al., 1991) . Animals were placed into individual Perspex arenas, 24 ϫ 24 cm in diameter with 30-cm high transparent walls, for 25 min. Six rats were observed simultaneously, and every 10 s the following behaviors were scored by a sampling technique: 1) rearing; 2) sniffing with head turning; 3) walking; 4) grooming; and 5) immobility (resting). Ambulation was also expressed by a combined score of rearing, sniffing, and walking (ambulation ϭ 3 ϫ rearing ϩ 1 ϫ sniffing ϩ 2 ϫ walking scores). The representative scores of each behavioral component were summed up in 5-min blocks and analyzed statistically.
Novel Object Recognition. Novel object recognition was assessed 5 days postsurgery. A day before testing novel object recognition ability, the rats were placed into a cylindrical open-field arena of 80-cm diameter surrounded by a 60-cm high reflective aluminum wall for 3 min. During this period, the rats were allowed to habituate to the experimental surroundings. The next day, during the 1st session of the novel object recognition test, the rats were allowed to explore the same open-field apparatus for 5 min while two identical objects (A ϩ A) were placed into the arena. During the 2nd session, carried out 3 h after the 1st session, one of the two objects was replaced by a novel one (B ϩ A). The ratio of visiting the novel versus known objects illustrated the object recognition ability, i.e., the attention behavior. The total period spent with exploration of the objects during the 1st and 2nd sessions were recorded. The recognition ability of the novel object at the 2nd session was calculated in the following way: duration of exploration of the novel (B) object was divided by the duration of exploration of both novel (B) and familiar (A) objects and expressed in percentages.
Electrophysiology
Seven to 8-week-old male Wistar rats (Harlan) were decapitated, and 400-m transverse hippocampal slices were prepared with a self-constructed tissue chopper. The slices were transferred to a submerged recording chamber and adapted for at least 1 h at 33°C in artificial cerebrospinal fluid (124 mM NaCl, 4.9 mM KCl, 1.3 mM MgSO 4 , 2.5 mM CaCl, 1.2 mM KH 2 PO 4 , 25.6 mM NaHCO 3 , and 10 mM glucose 10, pH7.4).
The Schaffer collateral was locally stimulated by a monopolar stimulation electrode (impedance 20 Ϫ 150 ⍀; Sprint Metall Work, Reichshof, Germany) using a constant current, biphasic stimulus generator (voltage, 1-5 V; impulse duration, one polarity 0.1 ms and whole impulse 0.2 ms) (2100; AM-Systems Isolated Pulse Stimulator; AM-Systems, Carlsborg, WA). Field excitatory postsynaptic potentials (fEPSPs) were recorded from the stratum radiatum with glass electrodes (borosilicate glass with filament, 1-5 MOhm, diameter: l.5 mm, tip diameter: 3-20 m) filled with experimental solution. The field potentials were filtered by a low-pass filter (5 kHz). For the statistical analysis of the experiments, the slope of the fEPSP was determined. Recording, analysis, and supervision of the experiments were performed by means of a software program (PWIN), which was developed at the Leibniz Institute for Neurobiology (Department of Neurophysiology) in Magdeburg, Germany. LTP was induced using a theta burst stimulation protocol (four times two paired pulses were applied in intervals of 200 ms, the interval between the paired pulses was 10 ms, and the width of a single pulse was 0.2 ms).
Effect of A-705253 on Spectrin Cleavage in Hippocampal Slice Cultures
Hippocampal slices were prepared from 9 to 11-day-old Wistar rats. Slices, 350-m thick, were placed on Millicell single-well PCF inserts (Millipore, Schwalbach, Germany) in 6-well cell culture plates (Greiner Bio-One GmbH, Frickenhausen, Germany) and kept in an incubator for 8 days at 34°C with 5% CO 2 air. The slices were cultured in medium A [25 mM HEPES, pH 7.3, 40% basal medium Eagle with Earle's salt, 25% horse serum, 25% Earle's balanced salt solution, 1 mM GlutaMAX (Invitrogen GmbH, Karlsruhe, Germany), and 28 mM glucose] for the first 3 days. Thereafter, medium A was replaced with Neurobasal A medium (Neurobasal A medium, 1 mM GlutaMAX, and 25 mM glucose; Invitrogen GmbH), and the slices were kept in culture for an additional 5 days. Neurobasal A medium was replaced twice a week.
After cultivation of the hippocampal slices for 8 days, the medium was aspirated and replaced with 1 ml of Neurobasal A medium. A total of 0.001 ml of different A-705253 inhibitor solutions at 10, 1, and 0.1 mM was added, respectively. After a 30-min incubation at 34°C with 5% CO 2 air, NMDA was added (10 M final concentration) and incubated for 5 h at 34°C with 5% CO 2 air. After this time, the slices were collected in 1.5-ml Eppendorf tubes and solubilized by the addition of 0.025 ml of lysis buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10% sucrose, 0.1% CHAPS, 1 mM dithiothreitol, 1:25 CompletePlus (Roche Diagnostics GmbH, Mannheim, Germany), and 1:100 phosphatase inhibitor cocktail set II (Calbiochem-Merck Biosciences GmbH, Darmstadt, Germany). Slices were homogenized with a plastic pistill and kept on ice for 5 min. The insoluble material was removed by centrifugation for 5 min at 13,000 rpm and 4°C, and the supernatant was collected. Supernatant protein concentrations were determined with MicroBCA (Pierce Inc., Rockford, IL). Samples (equal total protein of 20 g/ lane) were mixed with NuPAGE LDS sample buffer 4ϫ (Invitrogen GmbH), heated for 5 min at 95°C, and thereafter resolved by 4 to 12% SDS Ϯ polyacrylamide gel electrophoresis (Invitrogen GmbH). After transfer of proteins to nitrocellulose membranes, the proteins were analyzed by immunoblotting using a murine monoclonal antibody (mAB 1622; Chemicon) specific for spectrin and calpain-mediated spectrin breakdown products (SBDPs) followed by a peroxidase-conjugated secondary sheep anti-mouse antibody (A6782; Sigma-Aldrich) and a peroxidase substrate. To determine the percentage inhibition, the integrated optical density of the SBDPs in the presence and absence of inhibitor was determined using the VersaDoc Imaging System (Bio-Rad Laboratories GmbH, Mü nchen, Germany).
Results
Calpain Inhibition Markedly Attenuates Degeneration of Cholinergic Fibers after Excitotoxic Lesion of the Nucleus Basalis Magnocellularis. We analyzed the effect of calpain inhibition on the cholinergic innervation of the parietal neocortex after induction of an excitotoxic insult to the nucleus basalis magnocellularis in rats. Immunostaining visualized ChAT-positive cholinergic innervation fibers in the parietal neocortex (Fig. 1, 2) , and fiber density was measured in the superficial sublayer of the layer V as described in Horvath et al. (2000) . The ChAT-positive fiber density ipsilaterally to the lesion was compared with the intact contralateral side and the percentage of fiber loss in the various experimental groups summarized in Fig. 3 . Injection of NMDA to the NBM decreased the density of the ChAT-positive fibers in the parietal cortex by 50%. Application of 2.5 mg/kg MK-801 nearly completely prevented this decrease. The calpain inhibitor A-705253 dose-dependently protected the cholinergic neurons and their projection fibers jpet.aspetjournals.org against the excitotoxic injury and reduced the fiber degeneration with 44 and 49% with 3 and 10 mg/kg, respectively. Application of 10 mg/kg A-705253 did not affect the density of the cholinergic innervation, when given to sham-treated animals.
Calpain Inhibition Decreased Microglia Activation after Excitotoxic Lesion of the Nucleus Basalis Magnocellularis. We further sought to examine whether calpain inhibition would prevent microglial activation that normally accompanies neurodegenerative processes. Therefore, we measured the area of microglial activation at the level of the NBM injection by staining microglia for integrin. Injection of NMDA strongly increased this area, which corresponds to the spread of the neurotoxin in the injection locus (Harkany et al., 2000) (Figs. 4 and 5) . When rats were treated with cal- Fig. 1 . Anatomical description of studying the cholinergic system after NBM lesion with NMDA. A, the posterior part of the NBM was lesioned, and most of the magnocellular cholinergic neurons are absent after lesion (lower left panel, which is the magnification of the nucleus basalis area outlined by dashed lines at A). The parietal neocortex of lesioned rat represents a marked loss of ChAT-positive fibers (middle left panel). The precise anatomical region between parietal cortex area 1 (Par1; primary somatosensory cortex) and parietal cortex area 2 (Par2; supplementary somatosensory cortex) (Zilles 1985) , where most of the areas were sampled for quantitative measurements of fiber density, is outlined by dashed lines. B and the right panels represent the nonlesioned control side of the same rat. The bar in B is 1 mm. Fig. 2 . Photomicrographs of cholinergic innervation of the parietal neocortex in 5 groups of animals: sham-operated and vehicle-treated, NMDA-treated and vehicle-injected, NMDA-treated and A-705253-injected in three different doses of 1, 3, and 10 mg/kg (labeled 1, 3, and 10, respectively). Quantitative measurement of fiber density was performed between the two arrows in the superficial part of layer V. The bar at the right represents 100 m. pain inhibitor A-705253, the area of activation was dosedependently decreased, and it reached significance at a dose of 3 mg/kg. The NMDA receptor antagonist MK-801 also strongly reduced the area size of microglia activation.
Calpain Inhibition As Well As NMDA Lesioning Does Not Affect Behavior in the Small Open-Field Test. We further examined whether NMDA lesioning of the NBM or the drug treatment itself would influence the rats ability to perform spontaneous behavior in an open-field test (experiments were performed blindly). No significant effects of the NMDA lesion and of the treatment with A-705253 were recorded at day 4 after the lesion. The different components of ambulatory behavior, i.e., rearing, walking, and sniffing with head movements, were not different from sham-treated control levels (data are not shown). Time spent with grooming and immobility was also unaltered (Fig. 6 ). Ambulation in general was not influenced by the different experimental manipulation. Therefore, the general condition to perform spontaneous behavior was not significantly altered by the lesion and by drug treatment.
Calpain Inhibition Attenuated Cognitive Deficits Occurring after Excitotoxic Lesion of the Nucleus Basalis Magnocellularis. After habituation to the openfield box, attention was tested at day 6 (5 days after surgery; experiments were performed blindly). The results obtained are shown in Fig. 7A . Spontaneous exploration of different objects placed in the open-field arena was not influenced by the lesion or by the treatments. MK-801-treated rats explored somewhat less, but this change was not significant. The objects were placed on the floor of the open field, and thus they could be approached by horizontal ambulation. This was not different among the groups.
Recognizing the novel object in contrast to the familiar one was markedly decreased by the NMDA lesion (Fig. 7B) . Treatment with A-705253 dose-dependently prevented the deficit. ANOVA revealed a significant difference between sham control and lesioned and A-705253-treated groups (p Ͻ 0.005). The smallest dose of A-705253 was ineffective. The dose of 3 mg/kg attenuated the effect of the NMDA lesion, but the interference just approached statistical significance (p ϭ 0.074). However, performance of this group was closer to the values of sham controls (p ϭ 0.104). The highest dose of 10 mg/kg completely prevented the effect of lesion (p Ͻ 0.005). The NMDA-lesioned group that was treated with MK-801 also displayed an attention level to novel stimuli comparable with the sham-lesioned controls.
Calpain Inhibition Did Not Affect NMDA ReceptorDependent LTP. To examine whether general NMDA receptor-mediated physiological functions and related intracel- 
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at ASPET Journals on April 30, 2017 jpet.aspetjournals.org lular signaling cascades were affected by calpain inhibition, we analyzed LTP during administration of A-705253 in hippocampal slices (Fig. 8, A and B) . Calpain inhibition by A-705253 did not affect LTP at 100 nM, which is comparable with brain levels of A-705253 at the dose of 10 mg/kg (Supplemental Fig. 1 ). We also tested the peptidic inhibitor ALLN for possible effects on LTP (Fig. 9, A and B) , but we did not detect any LTP suppression. Basic synaptic transmission was also unaltered, as assessed by the input/output relation (Figs. 8C and 9C ). To determine whether the LTP protocol used in this study was indeed NMDA receptor-dependent, we used the same LTP induction paradigm during treatment with the NMDA receptor blocker APV (Fig. 9D) . LTP was completely blocked under this condition, indicating that the LTP induction with our tetanization paradigms in CA1 was indeed NMDA receptor-dependent.
Calpain Was Activated by NMDA in Hippocampal Slice Cultures and Dose-Dependently Inhibited by A-705253. To examine whether application of NMDA activates calpain in neurons, and whether A-705253 sufficiently inhibits the activated calpain, we cultured rat hippocampal slices and exposed them to NMDA in the presence or absence of different concentrations of A-705253. Spectrin was cleaved under 10 M NMDA treatment into its spectrin degradation products of 150/145 kDa (Fig. 10A) , indicating that calpain was indeed activated in neurons treated with NMDA. Application of A-705253 dose-dependently prevented calpain activation, as indicated by a decrease of SBDPs. The calculated IC 50 is 408 nM ϭ 29 nM for free calpain inhibitor (considering 93% protein binding for A-705253; Fig. 10B ). 
Discussion
Excitotoxic cell death has been discussed as a common principle for several progressive neurological disorders (Lipton and Rosenberg, 1994; Harkany et al., 2000; Mattson, 2004) . Inadequate control over NMDA receptor stimulation causes excessive calcium influx into neurons, activating a subset of intracellular Ca 2ϩ -dependent signaling cascades. As a result, affected cells perish, can eventually die, and consequently the functionality of affected brain areas is impaired. During this process, Ca 2ϩ -activated calpain cleaves several proteins that are involved in cell death signaling. For example, Wu et al. (2004) provide data that cleavage of calcineurin by calpain contributes to neuronal degeneration. Xu et al. (2007) could show that truncation of mGluR1␣ by calpain is essential to excitotoxicity. Furthermore, collapsin response mediator-protein 3 triggers neuronal death after cleavage by calpain (Hou et al., 2006) . In a more chronic model, Kim et al. (2007) could show that degeneration of cortical neurons in vitro depends on calpain cleavage of p35. If calpain is part of such degenerative cascades, then inhibition of calpain should attenuate neuronal decline. Indeed, Caba et al. (2002) could show that inhibition of calpain was neuroprotective in hippocampal slice cultures exposed to NMDA receptor overstimulation. In vivo, Chiu et al. (2005) revealed that calpain inhibition should reduce neurodegeneration in the rat retina. For these reasons, calpain has been discussed as a target for neurodegenerative disorders (Huang and Wang, 2001; Zatz and Starling, 2005; Saez et al., 2006) .
The data presented here strongly suggest calpain that inhibition by A-705253 is neuroprotective in a model of NMDA-induced cholinergic cell lesion. After such cholinergic basal forebrain damage by NMDA and subsequent cholinergic cortical denervation, learning behavior was compromised as assessed in a novel object recognition test, in which a dose-dependent protective effect of A-705253 on behavioral decline was demonstrated. Anatomical findings further confirmed the neuroprotective effect of calpain inhibition. Both the degree of cholinergic denervation in the parietal cortex and the extent of microglia activation around the injection in the NBM were markedly and dose-dependently attenuated by the inhibitor. The effective dose was shown to inhibit calpain in vivo, as determined by experiments on tau phosphorylation in the rat brain (data not shown). The present findings support the conclusion that inhibition of calpain not only prevents neuronal decline in an animal model of excitotoxicity, but it also attenuates accompanying behavioral deficits and neuropathology, including gliosis.
Most of the previous studies on calpain inhibition used peptidic inhibitors that are not specific for calpain. Furthermore, due to low solubility, these compounds had to be applied at high concentrations, which again may have resulted in unspecific side effects. The compound used in the present 
Calpain Inhibition Prevents Excitotoxicity in Vivo 349
at ASPET Journals on April 30, 2017 jpet.aspetjournals.org study was recently introduced by Lubisch et al. (2003) , and it has a high inhibitory potency for calpain (K i ϭ 27 nM) without affecting the proteasome (K i Ͼ 10,000 nM) and caspases (K i Ͼ 10,000 nM). Therefore, the observed neuroprotective effects are probably mediated by inhibition of calpain and not by reducing proteasome or caspase activity. This finding is important in light of the fact that the proteasome complex contributes to a variety of neurodegenerative disorders (Rubinsztein, 2006; Pan et al., 2008) . A-705253 has previously been shown to rapidly and effectively penetrate myocardial tissues, and it exerts its effects on cellular targets within minutes after perfusion (Neuhof et al., 2003 (Neuhof et al., , 2004 , making it an ideal compound for studying calpain in vivo.
Excitotoxicity-induced neurodegeneration is caused by an overactivation of the NMDA receptor (Liu et al., 2007; von Engelhardt et al., 2007) . Consequently, blockade of the NMDA receptor has been widely discussed and tested as a pharmacological target for excitotoxicity-induced neurodegeneration (Harkany et al., 1999; Lipton 2004; Gardoni and Di Luca, 2006) . However, one of the caveats of this approach is that a functional NMDA receptor is indispensable for a variety of physiological and behavioral brain functions, including synaptic plasticity, long-term potentiation, and memory performance (Lynch, 2004; Fedulov et al., 2007) , and it is well established that blockade of the NMDA receptor impairs cognition (Morris, 1989; Fedulov et al., 2007) . In the study presented here, calpain inhibition by A-705253 was similarly effective as MK-801 against the excitotoxic insult. This indicates that blocking the calpain-mediated downstream pathway in specific neurotoxic conditions can be as effective in suppressing the NMDA receptor. Therefore, we investigated whether calpain inhibition would also prevent or affect normal physiological function of the NMDA receptor, as does MK-801. To address this question, we examined LTP in the hippocampal CA1 region under exposure to A-705253. LTP at the Schaffer collateral requires functional NMDA receptors (Harris et al., 1984; Reymann et al., 1989) . We did not detect any LTP impairment during calpain inhibition, allowing the conclusion that normal NMDA receptor function and downstream calcium-dependent mechanisms of synaptic plasticity are not affected by A-705253 treatment. The concentration used effectively inhibited calpain in hippocampal slices as well as cultured neurons, as determined by tau and dynamin degradation as well as tau hyperphosphorylation (data not shown). LTP during application of the peptidic calpain inhibitor ALLN also yielded LTP equal to controls. To ensure that our LTP protocol indeed induces NMDA receptor-dependent LTP, the NMDA blocker (2R)-amino-5-phosphonovaleric acid (APV) was applied under the same protocol. Under this condition, LTP was completely prevented. Therefore, it is unlikely that calpain is involved with all of the cascades induced by NMDA receptor activation, and it may thus be a more appropriate target for neuroprotection than the NMDA receptor itself.
With the exception of traumatic brain injury and stroke, most neurodegenerative diseases progress slowly over a period of many years. The excitotoxic insult used in this model induced a more rapid decline, and behavioral deficits were already measurable after days. At this point, it is not known whether calpain inhibition would also prevent a more chronic neurodegeneration of the nucleus basalis, as observed in Alzheimer's disease. Further experiments are needed to evaluate whether calpain inhibition can also counteract a chronic loss of cholinergic cells.
Taken together, this study shows that inhibition of calpain 1) is sufficient to prevent NMDA-induced degeneration of NBM and its associated cholinergic fiber projections, 2) attenuates behavioral deficits associated with such lesion, and 3) does not interfere with the physiological role of the synaptic NMDA receptor. These findings indicate that inhibiting calpain could be an attractive neuroprotective strategy, without interfering with physiologically relevant NMDA receptorrelated processes and its behavioral functions. 
